CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients

Varmavuo, Ville; Mäntymaa, Pentti; Silvennoinen, Raija; Nousiainen, Tapio; Kuittinen, Taru; Jantunen, Esa

doi:10.1111/j.1537-2995.2012.03848.x

Cited by 31 publications

(28 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data were confirmed in three recent retrospective studies by Varmavuo et al 11,12 and Roug et al; 13 they all showed higher proportions of CD38 − among the CD34 + cells in patients who received plerixafor, compared with G-CSF only or chemomobilization, with similar engraftment kinetics.…”

Section: Cd34 + Stem Cell Dose For Autologous Transplant In the Plerisupporting

confidence: 77%

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Saraceni

Shem‐Tov

Olivieri

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Although stem cell mobilization has been performed for more than 20 years, little is known about the effects of mobilizing agents on apheresis composition and the impact of graft cell subsets on patients' outcome. With the increasing use of plerixafor and the inclusion of poor mobilizers in autologous transplant procedures, new parameters other than CD34 + stem cell dose are emerging; plerixafor seems to mobilize more primitive CD34 + /CD38 − stem cells compared with G-CSF, but their correlation with stable hematopoietic engraftment is still obscure. Immune recovery is as crucial as hematopoietic reconstitution, and higher T and natural killer cells infused within the graft have been correlated with better outcome in autologous transplant; recent studies showed increased mobilization of immune effectors with plerixafor compared with G-CSF, but further data are needed to clarify the clinical impact of these findings. In the allogeneic setting, much evidence suggests that mobilized T-cell alloreactivity is tempered by G-CSF, probably with the mediation of dendritic cells, even though no clear correlation with GVL and GVHD has been found. Plerixafor is not approved in healthy donors yet; early data suggest it might mobilize a GVHD protective balance of immune effectors, but further studies are needed to define its role in allogeneic transplant.

show abstract

Section: Cd34 + Stem Cell Dose For Autologous Transplant In the Plerisupporting

confidence: 77%

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Saraceni

Shem‐Tov

Olivieri

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Subsequent reports showed similar results. However, none of these groups described their gating strategies or showed figures depicting how “CD38 dim ” “CD38 low ” or “CD38 negative ” cells had been defined . Various groups have developed the model of a hematopoietic tree, describing the differentiation from the earliest CD34+ MPPs to lineage‐committed CD34+ precursors giving rise to defined blood cells.…”

Section: Discussionmentioning

confidence: 99%

“…To enhance CD34+ cell release from the BM, plerixafor, a chemokine receptor Type 4 (CXCR4) antagonist, can be given in addition to G‐CSF with or without chemotherapy . Several authors investigated the composition of PBSC grafts after various mobilization methods . However, preanalytic methods including the use of fluorochromes and antibody combinations to characterize PBSC by flow cytometry and analysis techniques reported are different.…”

mentioning

confidence: 99%

Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes

Worel¹,

Frank

Frech

et al. 2017

Transfusion

View full text Add to dashboard Cite

In contrast to the findings of other authors, our study shows a clear shift toward more committed CD34+ subsets after plerixafor in poor mobilizers and elucidates the importance of informative surface markers like CD45RA and CD133 in addition to CD38 to discriminate earlier from more committed CD34+ cells. Further studies are needed to analyze whether these findings have an impact on clinical outcome.

show abstract

“…24,34,35 Despite a relatively high expression on all HSPC subsets, its mean fluorescence intensity values were clearly lower on CD133 + HSPC subtypes than on more committed CD34 stages. However, owing to the substantial overlap between the different CD34 subtypes, CD38 could never be used to unambiguously separate early from more committed progenitors.…”

Section: Discussionmentioning

confidence: 99%

Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources

Dmytrus

Matthes‐Martin

Pichler

et al. 2016

Bone Marrow Transplant

View full text Add to dashboard Cite

Flow cytometric routine CD34 analysis enumerates hematopoietic stem and progenitor cells irrespective of their subpopulations although this might predict engraftment dynamics and immune reconstitution. We established a multi-color CD34 assay containing CD133, CD45RA, CD10, CD38 and CD33. We examined PBSC, donor bone marrow (BMd) and BM of patients 1 year after allografting (BM1y) regarding their CD34 subset composition, which differed significantly amongst those materials: the early CD45RA − CD133 + CD38 low subpopulations were significantly more frequent in PBSC than in BMd, and very low in BM1y. Vice versa, clearly more committed CD34 stages prevailed in BM, particularly in BM1y where the proportion of multi-lymphoid and CD38 ++ B-lymphoid precursors was highest (mean 59%). CD33 was expressed at different intensity on CD45RA ± CD133 ± subsets allowing discrimination of earlier from more committed myeloid precursors. Compared with conventional CD34 + cell enumeration, the presented multicolor phenotyping is a qualitative approach defining different CD34 subtypes in any CD34 source. Its potential impact to predict engraftment kinetics and immune reconstitution has to be evaluated in future studies.

show abstract

CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients

Abstract: Plerixafor appears to have effects on blood stem cell graft composition in myeloma patients. A higher number of grafts should be evaluated in regard to cellular content and longer follow-up of the patients is needed to evaluate the potential clinical impact of graft content.

Cited by 31 publications

References 35 publications

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective

Influence of plerixafor on the mobilization of CD34+ cell subpopulations and lymphocyte subtypes

Multi-color immune-phenotyping of CD34 subsets reveals unexpected differences between various stem cell sources

Contact Info

Product

Resources

About